Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

Rituximab/chemotherapy relapsed and refractory B cell lymphoma patients have a poor overall prognosis, and it is urgent to develop novel drugs for improving the therapy outcomes. Here, we examined the therapeutic effects of chidamide, a new histone deacetylase (HDAC) inhibitor, on the cell and mouse...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Kai, Wu, Ji-Chuan, Li, Xi-Ya, Li, Ran, Zhang, Qun-ling, Chang, Jin-Jia, Liu, Yi-Zhen, Xu, Chun-Hui, Zhang, Jia-Ying, Sun, Xiao-Jian, Gu, Juan J., Guo, Wei-Jian, Wang, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486747/
https://www.ncbi.nlm.nih.gov/pubmed/34599153
http://dx.doi.org/10.1038/s41419-021-04187-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486747/
https://www.ncbi.nlm.nih.gov/pubmed/34599153
http://dx.doi.org/10.1038/s41419-021-04187-5

Ejemplares similares